BioBeats is a company.
BioBeats has raised $3.6M across 2 funding rounds.
Key people at BioBeats.
BioBeats has raised $3.6M in total across 2 funding rounds.
BioBeats has raised $3.6M in total across 2 funding rounds.
BioBeats's investors include Future Positive Capital, Caffeinated Capital, Dreamers VC, ENIAC Ventures, Independent, IVP, Miramar Ventures, NextGen Venture Partners, Offline Ventures, Relay Ventures, Revolution, Sierra Ventures.
Key people at BioBeats.
# BioBeats: High-Level Overview
BioBeats is a medical technology company revolutionizing hypertension diagnosis and management through FDA-cleared, cuff-less blood pressure monitoring systems.[1][2] The company develops AI-driven wearable devices that provide continuous, non-invasive, medical-grade measurements of vital signs including blood pressure, pulse rate, respiratory rate, and blood oxygen saturation.[1] BioBeats serves healthcare providers and patients globally, operating in hospitals, clinics, home care settings, and clinical research environments.[1] The company's core mission is to ensure all hypertension patients are monitored and managed effectively by empowering physicians with accurate, real-time data to optimize patient care and reduce misdiagnosis.[2][3]
The company has achieved significant commercial momentum, recently securing $50 million in Series B financing led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical.[7] This capital infusion is being deployed to expand commercialization in the United States, with the company building out a field sales team to drive adoption of its novel ambulatory blood pressure monitoring (ABPM) system.[7] BioBeats operates with offices in Tel Aviv, Israel (its headquarters at 26 Hamagshimim, Petah Tikva) and Boca Raton, Florida, positioning itself to serve both the European and North American markets.[1][7]
# Core Differentiators
# Role in the Broader Tech Landscape
BioBeats operates at the intersection of several powerful healthcare trends: the shift toward remote patient monitoring, the digitization of chronic disease management, and the growing emphasis on continuous rather than episodic health data.[1][3] The company is riding the wave of wearable technology adoption and AI-driven clinical decision support, addressing a critical gap in hypertension management—a condition affecting over 100 million patients in the U.S. alone.[7]
The timing is particularly favorable as healthcare systems seek to reduce costs while improving outcomes, and as regulatory bodies have become more receptive to innovative monitoring technologies.[7] BioBeats' location in Israel's "Silicon Wadi" provides access to deep technical talent and research institutions, while its dual headquarters structure (Tel Aviv and Boca Raton) positions it to influence both European and North American healthcare ecosystems.[1]
# Quick Take & Future Outlook
BioBeats is well-positioned to become a standard-of-care solution for hypertension monitoring, similar to how patch-worn ambulatory ECG monitoring transformed cardiac care.[7] The company's recent $50 million Series B round signals strong investor confidence and provides the capital needed to scale commercialization aggressively. With world-class venture investors now on its board and a clear clinical value proposition, BioBeats is likely to drive broader adoption of ABPM technology and reshape how hypertension is diagnosed and managed globally.
The company's next phase will focus on converting clinical validation into widespread clinical adoption, expanding its field sales presence, and potentially extending its platform to adjacent chronic disease monitoring applications. As healthcare systems increasingly prioritize continuous monitoring and remote care delivery, BioBeats' technology addresses a fundamental need in the market.
BioBeats has raised $3.6M across 2 funding rounds. Most recently, it raised $3.0M Seed in August 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2018 | $3.0M Seed | Future Positive Capital | |
| Jul 1, 2013 | $650K Seed | Caffeinated Capital, Dreamers VC, ENIAC Ventures, Independent, IVP, Miramar Ventures, NextGen Venture Partners, Offline Ventures, Relay Ventures, Revolution, Sierra Ventures, Slow Ventures, Howard Lindzon, Softbank Group, TQ Ventures, Tribeca Venture Partners, UP.Partners, Webb Investment Network, Wing Venture Capital, Chris Hughes, Erik Moore, Esther Dyson, Jim Pallotta, Nate Matherson |